---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058635"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:26:18.656080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024

## Summary
- Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.
- Net loss of $11.6M vs $12.8M in Q1 2023; R&D expenses $10.3M (down from $11.7M).
- Collaboration revenue of $2.0M from Kaken Pharmaceutical agreement.
- CAHmelia-203 analyses show higher GC dose and drug compliance correlate with larger A4 reductions.
- Topline data from CAHmelia-204 (adult CAH) and interim dose-ranging from CAHptain-205 (pediatric) expected Q3 2024.

## SEC filing metadata
- accession: 0000950170-24-058635
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/0000950170-24-058635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/sprb-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058635
- JSON: https://secwatch.observer/filing/0000950170-24-058635.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058635.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/0000950170-24-058635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.